Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Jen Yu

Showing results (441-450 of 478) with videos related to

Pageof 48
Sort By:
The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.
Oncotarget|July 25, 2016
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patientsKuo-Hsuan Hsu, Jeng-Sen Tseng, Chih-Liang Wang, et al.
Emerging Infectious Diseases|March 14, 2023
Emergence and Persistent Dominance of SARS-CoV-2 Omicron BA.2.3.7 Variant, TaiwanPei-Lan Shao, Hsiao-Chen Tu, Yu-Nong Gong, et al.
Cancer Research|November 21, 2024
Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-SmokersYun-Ching Chen, Chia-Lang Hsu, Hui-Min Wang, et al.
International Journal of Antimicrobial Agents|March 25, 2008
Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance studyLu-Cheng Kuo, Chong-Jen Yu, Ming-Long Kuo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Nature Immunology|May 12, 2026
Epigenetic reprogramming of T cell metabolism restores function and enhances anti-tumor immunity in lung cancerYi-Chieh Wu, Shih-Feng Yang, Yu-Ting Lee, et al.
Oncotarget|May 19, 2016
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking statusChia-Hung Hsu, Chien-Hua Tseng, Chun-Ju Chiang, et al.
Cancer Cell|January 3, 2008
MicroRNA signature predicts survival and relapse in lung cancerSung-Liang Yu, Hsuan-Yu Chen, Gee-Chen Chang, et al.
Pageof 48

Showing results (441-450 of 478) with videos related to

Sort By:
Pageof 48
The New England Journal of Medicine|September 21, 2020
Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung CancerYi-Long Wu, Masahiro Tsuboi, Jie He, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S Herbst, Yi-Long Wu, Thomas John, et al.
Oncotarget|July 25, 2016
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patientsKuo-Hsuan Hsu, Jeng-Sen Tseng, Chih-Liang Wang, et al.
Emerging Infectious Diseases|March 14, 2023
Emergence and Persistent Dominance of SARS-CoV-2 Omicron BA.2.3.7 Variant, TaiwanPei-Lan Shao, Hsiao-Chen Tu, Yu-Nong Gong, et al.
Cancer Research|November 21, 2024
Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-SmokersYun-Ching Chen, Chia-Lang Hsu, Hui-Min Wang, et al.
International Journal of Antimicrobial Agents|March 25, 2008
Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance studyLu-Cheng Kuo, Chong-Jen Yu, Ming-Long Kuo, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Nature Immunology|May 12, 2026
Epigenetic reprogramming of T cell metabolism restores function and enhances anti-tumor immunity in lung cancerYi-Chieh Wu, Shih-Feng Yang, Yu-Ting Lee, et al.
Oncotarget|May 19, 2016
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking statusChia-Hung Hsu, Chien-Hua Tseng, Chun-Ju Chiang, et al.
Cancer Cell|January 3, 2008
MicroRNA signature predicts survival and relapse in lung cancerSung-Liang Yu, Hsuan-Yu Chen, Gee-Chen Chang, et al.
Pageof 48